药物发现论文趋势 2023–2026

分子与蛋白设计

统计范围:NeurIPS、ICLR、ICML、CVPR 四个会议,2023–2026 年,共 578 篇被归入该主题的论文。

主要结论

每年论文数

各会议论文数

按年份和会议统计

药物发现论文数,按年份和会议
年份NeurIPSICLRICMLCVPR合计
20232122201679
202449234211125
202564483912163
2026100376311211

代表论文

按年份和会议均匀挑选,方便快速看到每一届的样貌

全部药物发现论文

共 578 篇,第 1 / 12 页

  1. CVPR 2026A Polynomial Chaos Framework for Causal Discovery in Nonlinear Uncertain
  2. CVPR 2026Beyond the Static World Continual Category Discovery under Visual Drift
  3. CVPR 2026Decouple Your Discovery and Memory in Continual Generalized Category Discovery
  4. CVPR 2026Differences That Matter Auditing Models for Capability Gap Discovery and
  5. CVPR 2026Geometric-Aware Hypergraph Reasoning for Novel Class Discovery in Point Cloud
  6. CVPR 2026H-Sets Hessian-Guided Discovery of Set-Level Feature Interactions in Image Classifiers
  7. CVPR 2026Learning Like Humans Analogical Concept Learning for Generalized Category Discovery
  8. CVPR 2026Seeing Through the Shift Causality-Inspired Robust Generalized Category Discovery
  9. CVPR 2026TAR Token-Aware Refinement for Fine-grained Generalized Category Discovery
  10. CVPR 2026TRIDENT A Trimodal Cascade Generative Framework for Drug and RNA-Conditioned
  11. CVPR 2026Unsupervised Monocular 3D Keypoint Discovery from Multi-View Diffusion Priors
  12. ICLR 2026A Hierarchical Circuit Symbolic Discovery Framework for Efficient Logic Optimization
  13. ICLR 2026Adaptive Gaussian Expansion for On-the-fly Category Discovery
  14. ICLR 2026Bures Generalized Category Discovery
  15. ICLR 2026CAPSUL: A Comprehensive Human Protein Benchmark for Subcellular Localization
  16. ICLR 2026Causal Discovery in the Wild: A Voting-Theoretic Ensemble Approach
  17. ICLR 2026Causal Discovery via Quantile Partial Effect
  18. ICLR 2026ConfHit: Conformal Generative Design via Nested Testing
  19. ICLR 2026Differentially Private Domain Discovery
  20. ICLR 2026Disentangled representation learning through unsupervised symmetry group discovery
  21. ICLR 2026Drugging the Undruggable: Benchmarking and Modeling Fragment-Based Screening
  22. ICLR 2026DrugTrail: Explainable Drug Discovery via Structured Reasoning and Druggability‑Tailored Preference Optimization
  23. ICLR 2026Exploring Synthesizable Chemical Space with Iterative Pathway Refinements
  24. ICLR 2026Flow Expansion via Verifier-Constrained Noised State Space Exploration
  25. ICLR 2026Formal Mechanistic Interpretability: Automated Circuit Discovery with Provable Guarantees
  26. ICLR 2026FragFM: Hierarchical Framework for Efficient Molecule Generation via Fragment-Level Discrete Flow Matching
  27. ICLR 2026From Concepts to Components: Concept-Agnostic Attention Module Discovery in Transformers
  28. ICLR 2026GEPA: Reflective Prompt Evolution Can Outperform Reinforcement Learning
  29. ICLR 2026GRAM-DTI: Adaptive Multimodal Representation Learning for Drug–Target Interaction Prediction
  30. ICLR 2026Hedonic Neurons: A Mechanistic Mapping of Latent Coalitions in Transformer MLPs
  31. ICLR 2026Influence without Confounding: Causal Discovery from Temporal Data with Long-term Carry-over Effects
  32. ICLR 2026Interpolation-Based Conditioning of Flow Matching Models for Bioisosteric Ligand Design
  33. ICLR 2026KGOT: Unified Knowledge Graph and Optimal Transport Pseudo-Labeling for Molecule-Protein Interaction Prediction
  34. ICLR 2026Multi-Condition Conformal Selection
  35. ICLR 2026Multi-state Protein Design with DynamicMPNN
  36. ICLR 2026On Discovering Algorithms for Adversarial Imitation Learning
  37. ICLR 2026Pallatom-Ligand: an All-Atom Diffusion Model for Designing Ligand-Binding Proteins
  38. ICLR 2026PepBenchmark: A Standardized Benchmark for Peptide Machine Learning
  39. ICLR 2026PRISM: Progressive Robust Learning for Open-World Continual Category Discovery
  40. ICLR 2026RECON: Robust symmetry discovery via Explicit Canonical Orientation Normalization
  41. ICLR 2026Reference Guided Skill Discovery
  42. ICLR 2026Refine Drugs, Don’t Complete Them: Uniform-Source Discrete Flows for Fragment-Based Drug Discovery
  43. ICLR 2026SAIR: Enabling Deep Learning for Protein-Ligand Interactions with a Synthetic Structural Dataset
  44. ICLR 2026Scaling Multi-Task Bayesian Optimization with Large Language Models
  45. ICLR 2026ShinkaEvolve: Towards Open-Ended and Sample-Efficient Program Evolution
  46. ICLR 2026SpectralGCD: Spectral Concept Selection and Cross-modal Representation Learning for Generalized Category Discovery
  47. ICLR 2026SYNC: Measuring and Advancing Synthesizability in Structure-Based Drug Design
  48. ICLR 2026Toward Safer Diffusion Language Models: Discovery and Mitigation of Priming Vulnerability
  49. ICML 2026Adaptive Symmetry Discovery for Dynamical System Identification
  50. ICML 2026APEX: Approximate-but-exhaustive search for ultra-large combinatorial synthesis libraries

在 Claude、Cursor 里直接问这个趋势

接上 Paperlist MCP 后,写综述、挑方向或准备投稿时,不用离开对话框就能拿到这页的数字:每年各会议的论文数、增长倍数、涨得最快的子方向和代表论文,AI 会按你的问题整理。

可以直接复制这句话问 AI

用 paperlist 查药物发现在 NeurIPS 2023–2026 的论文趋势,哪一年涨得最快?

AI 会调用的工具:get_topic_stats {"topic": "drug-discovery"}

两分钟接入 Paperlist MCP(Claude Code、Cursor、Codex、ChatGPT)

常见问题

2023–2026 年四大会议一共有多少篇药物发现论文?
共 578 篇,按年份分别是 2023 年 79 篇、2024 年 125 篇、2025 年 163 篇、2026 年 211 篇。
NeurIPS 2026 有多少篇药物发现论文?
NeurIPS 2026 有 100 篇药物发现论文,上一届是 64 篇。
ICLR 2026 有多少篇药物发现论文?
ICLR 2026 有 37 篇药物发现论文,上一届是 48 篇。
ICML 2026 有多少篇药物发现论文?
ICML 2026 有 63 篇药物发现论文,上一届是 39 篇。
CVPR 2026 有多少篇药物发现论文?
CVPR 2026 有 11 篇药物发现论文,上一届是 12 篇。
哪个会议的药物发现论文最多?
NeurIPS,2023–2026 年共 234 篇。

「健康与生命科学」下的其他主题